Some readers have recently been asking me about curcumin and Covid-19. Is it good or bad to be taking it if you contract coronavirus? Can it reduce your risk of contracting Covid-19? (See my post on vitamina D, incidentally.) I don’t know.
If I had any answers, believe me, I’d be publishing them…immediately.
Well, it just so happens that this afternoon I read a very interesting Science Daily article that may shed some light on this matter. It discusses the case study of ONE myeloma patient, in Wuhan, who was given an immunosuppressant drug, a monoclonal antibody, called tocilizumab. Here’s the link: https://www.sciencedaily.com/releases/2020/04/200403124931.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fmultiple_myeloma+%28Multiple+Myeloma+News+–+ScienceDaily%29
Okay, now that you’ve read the SD article, you can read the rest of my post.
The main use of tocilizumab is to treat rheumatoid arthritis. The interesting bit, as far as I’m concerned, though, is that tocilizumab blocks IL-6. Remember IL-6? I haven’t talked about IL-6 in a long time, but, simply put, it’s a really good friend of multiple myeloma. Aha…
And, by reducing the expression of IL-6, tocilizumab helps control the effects of what is known as a “cytokine storm” (read this April 1 New York Times article for a good explanation of what happens to Covid-19 patients when their immune systems go wacky and begin churning out too many cytokines, which can lead to vital organ failure: https://www.nytimes.com/2020/04/01/health/coronavirus-cytokine-storm-immune-system.html).
Okay, now for this: curcumin inhibits IL-6 AND suppresses the cytokines involved in cytokine storms. Yes, it does both the things that tocilizumab does, without all the side effects, which actually don’t look that bad–from a runny nose to urinary tract infections (well, okay, I’d rather not get a UTI!).
Does that mean that curcumin would work against coronavirus or indeed help lower our risk of getting this blasted virus? As I wrote above, I have no idea, even though, as we know, among other things, curcumin has anti-viral and anti-inflammatory properties.
All I can say is that this bit of news today is promising. Sure, this is only ONE single case study, but I can tell you that, on March 19, tocilizumab started being administered to 330 coronavirus patients in a hospital in Naples (Italy). At the end of this month, fingers crossed, we may have some results. Right now, Italian newspapers report that the director of this study has expressed “cautious optimism.” I also saw that the FDA has approved Phase III trials for treating Covid patients with tocilizumab.
We just have to wait and see…
But, while we’re waiting, I’m going to keep taking curcumin (actually, I’d never thought about stopping…!!!)…